Details
Stereochemistry | RACEMIC |
Molecular Formula | C6H11NO2 |
Molecular Weight | 129.157 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(CCC(O)=O)C=C
InChI
InChIKey=PJDFLNIOAUIZSL-UHFFFAOYSA-N
InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)
DescriptionSources: https://www.drugbank.ca/drugs/DB01080Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020427s010s011s012,022006s011s012s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22061175
Sources: https://www.drugbank.ca/drugs/DB01080
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020427s010s011s012,022006s011s012s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22061175
Vigabatrin is an anticonvulsant chemically unrelated to other anticonvulsants. Vigabatrin prevents the catabolism of GABA by irreversibly inhibiting the enzyme GABA transaminase. It is an analog of GABA, but it is not a receptor agonist. However, vigabatrin is not a potent inhibitor of GABA-T with a Ki of 10 mM. Vigabatrin increases brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by irreversibly inhibiting enzymes that catabolize GABA (gamma-aminobutyric acid transaminase, GABA-T). Duration of action is determined by rate of GABA-T re-synthesis. Vigabatrin may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. Vigabatrin is sold under the trade name SABRIL, it is indicated as adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
0.85 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SABRIL Approved UseSABRIL is an antiepileptic drug (AED) indicated for:
• Refractory Complex Partial Seizures in Adults
(1.1). It should be used as adjunctive therapy in
patients who have responded inadequately to
several alternative treatments. Launch Date1.25072638E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8331204/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
VIGABATRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
73 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8331204/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
VIGABATRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8331204/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
VIGABATRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
VIGABATRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Disc. AE: Sedation, Seizures... Other AEs: Weight gain, Depression... AEs leading to discontinuation/dose reduction: Sedation (9%) Other AEs:Seizures (2%) Status epilepticus (1%) Weight gain (6%) Sources: Page: p.745Depression (1%) Excitability (1%) Itching (1%) Headache (1%) Irritability (1%) Muscle pain (1%) Libido decreased (1%) |
2 g 2 times / day multiple, oral Highest studied dose Dose: 2 g, 2 times / day Route: oral Route: multiple Dose: 2 g, 2 times / day Sources: Page: p.460 |
healthy, 25.8 ± 8.2 n = 24 Health Status: healthy Age Group: 25.8 ± 8.2 Sex: M Population Size: 24 Sources: Page: p.460 |
|
4 g single, oral Highest studied dose Dose: 4 g Route: oral Route: single Dose: 4 g Sources: Page: p.460 |
healthy, 27.0 ± 8.2 n = 24 Health Status: healthy Age Group: 27.0 ± 8.2 Sex: M Population Size: 24 Sources: Page: p.460 |
|
3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: Page: p.81 |
unhealthy, 35 ± 11 n = 41 Health Status: unhealthy Condition: Complex Partial Seizures Age Group: 35 ± 11 Sex: M+F Population Size: 41 Sources: Page: p.81 |
|
90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Other AEs: Coma, Unconsciousness... Other AEs: Coma (common) Sources: Page: p.16Unconsciousness (common) Drowsiness (common) Vertigo (uncommon) Psychosis (uncommon) Apnea (uncommon) Respiratory depression (uncommon) Bradycardia (uncommon) Agitation (uncommon) Irritability (uncommon) Confusion (uncommon) Headache (uncommon) Hypotension (uncommon) Abnormal behavior (uncommon) Seizures (uncommon) Status epilepticus (uncommon) Speech disorder (uncommon) |
1500 mg 2 times / day multiple, oral Recommended Dose: 1500 mg, 2 times / day Route: oral Route: multiple Dose: 1500 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.1 |
Other AEs: Vision loss, Brain MRI signal changes... Other AEs: Vision loss Sources: Page: p.1Brain MRI signal changes Suicidal behavior Suicidal ideation Anemia Somnolence Fatigue |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Depression | 1% | 2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Excitability | 1% | 2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Headache | 1% | 2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Irritability | 1% | 2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Itching | 1% | 2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Libido decreased | 1% | 2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Muscle pain | 1% | 2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Status epilepticus | 1% Disc. AE |
2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Seizures | 2% Disc. AE |
2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Weight gain | 6% | 2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Sedation | 9% Disc. AE |
2 g 1 times / day multiple, oral Highest studied dose Dose: 2 g, 1 times / day Route: oral Route: multiple Dose: 2 g, 1 times / day Sources: Page: p.745 |
unhealthy, 16-63 n = 99 Health Status: unhealthy Condition: Epilepsy Age Group: 16-63 Sex: M+F Population Size: 99 Sources: Page: p.745 |
Coma | common | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Drowsiness | common | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Unconsciousness | common | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Abnormal behavior | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Agitation | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Apnea | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Bradycardia | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Confusion | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Headache | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Hypotension | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Irritability | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Psychosis | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Respiratory depression | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Seizures | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Speech disorder | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Status epilepticus | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Vertigo | uncommon | 90 g single, oral (max) Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: Page: p.16 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.16 |
Anemia | 1500 mg 2 times / day multiple, oral Recommended Dose: 1500 mg, 2 times / day Route: oral Route: multiple Dose: 1500 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.1 |
|
Brain MRI signal changes | 1500 mg 2 times / day multiple, oral Recommended Dose: 1500 mg, 2 times / day Route: oral Route: multiple Dose: 1500 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.1 |
|
Fatigue | 1500 mg 2 times / day multiple, oral Recommended Dose: 1500 mg, 2 times / day Route: oral Route: multiple Dose: 1500 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.1 |
|
Somnolence | 1500 mg 2 times / day multiple, oral Recommended Dose: 1500 mg, 2 times / day Route: oral Route: multiple Dose: 1500 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.1 |
|
Suicidal behavior | 1500 mg 2 times / day multiple, oral Recommended Dose: 1500 mg, 2 times / day Route: oral Route: multiple Dose: 1500 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.1 |
|
Suicidal ideation | 1500 mg 2 times / day multiple, oral Recommended Dose: 1500 mg, 2 times / day Route: oral Route: multiple Dose: 1500 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.1 |
|
Vision loss | 1500 mg 2 times / day multiple, oral Recommended Dose: 1500 mg, 2 times / day Route: oral Route: multiple Dose: 1500 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Refractory Complex Partial Seizures Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020427s000_ClinPharmR_P1.pdf#page=70 Page: 70.0 |
likely | weak (co-administration study) Comment: A 16% to 20% average reduction in total phenytoin plasma levels was reported (see label page 21) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020427s000_ClinPharmR_P1.pdf#page=70 Page: 70.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020427s000_ClinPharmR_P1.pdf#page=70 Page: 70.0 |
likely | weak (co-administration study) Comment: A 16% to 20% average reduction in total phenytoin plasma levels was reported (see label page 21) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020427s000_ClinPharmR_P1.pdf#page=70 Page: 70.0 |
||
Page: 22.0 |
no | no (co-administration study) Comment: No significant difference in pharmacokinetic parameters of vigabatrin were found after treatment with ethinyl estradiol and levonorgestrel; vigabatrin did not interfere significantly with the cytochrome P450 isoenzyme (CYP3A)-mediated metabolism of the contraceptive tested Page: 22.0 |
||
Page: 22.0 |
no | no (co-administration study) Comment: No significant difference in pharmacokinetic parameters of vigabatrin were found after treatment with ethinyl estradiol and levonorgestrel; vigabatrin did not interfere significantly with the cytochrome P450 isoenzyme (CYP3A)-mediated metabolism of the contraceptive tested Page: 22.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020427s000_ClinPharmR_P1.pdf#page=70 Page: 70.0 |
not significant | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020427s000_ClinPharmR_P1.pdf#page=70 Page: 70.0 |
not significant |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022006s000_ClinPharm.pdf#page=4 Page: 4.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. | 1999 Dec 10 |
|
Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation. | 1999 Jun 10 |
|
Psychiatric adverse events during vigabatrin therapy. | 1999 Oct 22 |
|
Visual field defect associated with vigabatrin: observational cohort study. | 1999 Oct 30 |
|
Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. | 1999 Sep |
|
[Visual field changes secondary to vigabatrin treatment]. | 2000 Dec 16-31 |
|
Effect of long-term vigabatrin administration on the immature rat brain. | 2000 Jun |
|
Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. | 2000 May |
|
Human brain GABA transaminase tissue distribution and molecular expression. | 2000 Sep |
|
Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. | 2001 |
|
The management of refractory idiopathic epilepsies. | 2001 |
|
Management strategies for refractory localization-related seizures. | 2001 |
|
Epileptic encephalopathy. | 2001 |
|
GABAergic mechanisms in epilepsy. | 2001 |
|
Behavioural effects of the new anticonvulsants. | 2001 |
|
Effects of antiepileptic drugs on cognition. | 2001 |
|
The long-term use of vigabatrin and lamotrigine in patients with severe childhood onset epilepsy. | 2001 |
|
GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux via reversal of the GABA transporter. | 2001 Apr 15 |
|
Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance. | 2001 Aug |
|
Newer antiepileptic drugs: advantages and disadvantages. | 2001 Aug |
|
Paradoxical reduction of synaptic inhibition by vigabatrin. | 2001 Aug |
|
Infantile spasms. | 2001 Feb |
|
Determination of the antiepileptics vigabatrin and gabapentin in dosage forms and biological fluids using Hantzsch reaction. | 2001 Feb |
|
Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. | 2001 Feb |
|
Prolonged epileptic blindness in an infant associated with cortical dysplasia. | 2001 Feb |
|
Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics. | 2001 Jan |
|
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). | 2001 Jan |
|
Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis? | 2001 Jul |
|
Influence of pyridoxal 5'-phosphate alone and in combination with vigabatrin on brain GABA measured by 1H-NMR-spectroscopy. | 2001 Jul 1 |
|
Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. | 2001 Jul 24 |
|
Spectrofluorimetric determination of vigabatrin and gabapentin in dosage forms and spiked plasma samples through derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole. | 2001 Jul-Aug |
|
Vigabatrin visual toxicity: evolution and dose dependence. | 2001 May |
|
Gamma-vinyl GABA reduces paired pulse inhibition in the rat dentate gyrus in vivo and in vitro. | 2001 May |
|
Randomized trial of vigabatrin in patients with infantile spasms. | 2001 Oct 23 |
|
Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake. | 2001 Sep |
|
Determination of vigabatrin in human plasma and urine by high-performance liquid chromatography with fluorescence detection. | 2001 Sep 5 |
Patents
Sample Use Guides
Refractory Complex Partial Seizures
Adults >16 years of age: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1500 mg twice daily (2.2).
Pediatrics 10 to 16 years of age: Treatment is based on body weight. Initiate therapy at 250 mg twice daily, increasing total daily dose per instructions.
The recommended maintenance dose is 1000 mg twice daily. Patients weighing more than 60 kg should be dosed according to adult recommendations (2.2).
Infantile Spasms
Initiate therapy at 50 mg/kg/day given in 2 divided doses increasing total daily dose per instructions to a maximum of 150 mg/kg/day given in 2 divided doses (2.3).
Given orally with or without food.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25062867
Vigabatrin inhibits the uptake of taurine in Caco-2 and MDCK cells to 34 ± 3 and 53 ± 2%, respectively, at a concentration of 30 mM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
609817
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
||
|
FDA ORPHAN DRUG |
135100
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
||
|
WHO-ATC |
N03AG04
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
||
|
LIVERTOX |
NBK548253
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
||
|
NDF-RT |
N0000175753
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
||
|
FDA ORPHAN DRUG |
905322
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
||
|
WHO-VATC |
QN03AG04
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5665
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
1712001
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
14851
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | RxNorm | ||
|
DB01080
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
D020888
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
Vigabatrin
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
VIGABATRIN
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
GR120KRT6K
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
C87611
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
SUB00048MIG
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
60643-86-9
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
SUPERSEDED | |||
|
5581
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
4821
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
2819
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
GR120KRT6K
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
100000079084
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
U-75
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
m11445
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | Merck Index | ||
|
68506-86-5
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
CHEMBL89598
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
63638
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY | |||
|
DTXSID4041153
Created by
admin on Fri Dec 15 16:58:40 UTC 2023 , Edited by admin on Fri Dec 15 16:58:40 UTC 2023
|
PRIMARY |
ACTIVE MOIETY